Skip to main content
Erschienen in: International Journal of Hematology 5/2015

01.11.2015 | Original Article

Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration–time curve in pediatric hematopoietic stem cell transplant recipients

verfasst von: Erika Watanabe, Takuro Nishikawa, Kazuro Ikawa, Hiroki Yamaguchi, Takanari Abematsu, Shunsuke Nakagawa, Koichiro Kurauchi, Yuichi Kodama, Takayuki Tanabe, Yuichi Shinkoda, Kazuaki Matsumoto, Yasuhiro Okamoto, Yasuo Takeda, Yoshifumi Kawano

Erschienen in: International Journal of Hematology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Optimizing systemic busulfan exposure, the area under the concentration–time curve (AUC), improves the outcomes for hematopoietic stem cell transplantation (HSCT). The AUC is conventionally calculated using six plasma concentrations (AUC0–∞) drawn after the first of 16 intravenous busulfan doses given as a 2-h infusion every 6 h. The aim of the present study was to develop limited sampling strategies using three or fewer busulfan concentrations to reliably calculate AUC0–∞ in patients undergoing HSCT. We investigated the pharmacokinetics of busulfan 46 times in 29 pediatric patients receiving intravenous busulfan. Limited sampling strategies using one, two, or three plasma busulfan concentrations were developed by multiple linear regression that showed excellent agreement with AUC0–∞. In single-point sampling strategies, the AUC0–∞ predicted based on C6 (trough level: busulfan plasma concentration 6 h after the start of the infusion) was significantly correlated with, and not statistically different from, actual values as follows: AUC0–∞ = 2556.5 C6 + 320.9 (r 2  = 0.929, P < 0.0001, mean bias 0.282 %, precision 7.91 %). In contrast, the predicted AUCs derived from the other sampling single points did not meet the criteria. The trough level well correlated with actual AUC0–∞, suggesting that this time-point is acceptable for busulfan monitoring.
Literatur
1.
Zurück zum Zitat Hoy SM, Lyseng-Williamson KA. Intravenous busulfan in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs. 2007;9:271–8.CrossRefPubMed Hoy SM, Lyseng-Williamson KA. Intravenous busulfan in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs. 2007;9:271–8.CrossRefPubMed
2.
Zurück zum Zitat Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871–8.PubMedCentralCrossRefPubMed Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871–8.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31–42.PubMed Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31–42.PubMed
4.
Zurück zum Zitat Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225–30.PubMed Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225–30.PubMed
5.
Zurück zum Zitat Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socié G, Méchinaud F, et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer. 2012;58(1):90–7.CrossRefPubMed Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socié G, Méchinaud F, et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer. 2012;58(1):90–7.CrossRefPubMed
6.
Zurück zum Zitat Nagasawa M, Mitsuiki N, Ono T, Takagi M, Oda H, Yasuhara M, et al. Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children. Int J Hematol. 2010;91(4):728–30.CrossRefPubMed Nagasawa M, Mitsuiki N, Ono T, Takagi M, Oda H, Yasuhara M, et al. Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children. Int J Hematol. 2010;91(4):728–30.CrossRefPubMed
7.
Zurück zum Zitat Sato M, Kako S, Matsumoto K, Oshima K, Akahoshi Y, Nakano H, et al. Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. Int J Hematol. 2015;101(5):497–504.CrossRefPubMed Sato M, Kako S, Matsumoto K, Oshima K, Akahoshi Y, Nakano H, et al. Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. Int J Hematol. 2015;101(5):497–504.CrossRefPubMed
8.
Zurück zum Zitat Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. 2008;14(20):1936–49.CrossRefPubMed Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. 2008;14(20):1936–49.CrossRefPubMed
9.
Zurück zum Zitat Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004;33(10):979–87.CrossRefPubMed Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004;33(10):979–87.CrossRefPubMed
10.
Zurück zum Zitat Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr. 1987;416:426–32.CrossRefPubMed Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr. 1987;416:426–32.CrossRefPubMed
11.
Zurück zum Zitat Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978;6(6):547–58.CrossRefPubMed Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978;6(6):547–58.CrossRefPubMed
12.
Zurück zum Zitat Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Higashi M, et al. Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation. Bone Marrow Transplant. 2010;45(3):602–4.CrossRefPubMed Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Higashi M, et al. Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation. Bone Marrow Transplant. 2010;45(3):602–4.CrossRefPubMed
13.
Zurück zum Zitat Okamoto Y, Nagatoshi Y, Kosaka Y, Kikuchi A, Kato S, Kigasawa H, et al. Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. Pediatr Transplant. 2014;18(3):294–301.CrossRefPubMed Okamoto Y, Nagatoshi Y, Kosaka Y, Kikuchi A, Kato S, Kigasawa H, et al. Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. Pediatr Transplant. 2014;18(3):294–301.CrossRefPubMed
14.
Zurück zum Zitat Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, et al. Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. Biol Blood Marrow Transplant. 2015;21(8):1471–8.CrossRefPubMed Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, et al. Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. Biol Blood Marrow Transplant. 2015;21(8):1471–8.CrossRefPubMed
15.
Zurück zum Zitat Takamatsu Y, Sasaki N, Eto T, Nagafuji K, Abe Y, Choi I, et al. Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. Int J Hematol. 2007;86(3):261–8.CrossRefPubMed Takamatsu Y, Sasaki N, Eto T, Nagafuji K, Abe Y, Choi I, et al. Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. Int J Hematol. 2007;86(3):261–8.CrossRefPubMed
16.
Zurück zum Zitat Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC, et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant. 2010;45(2):249–53.CrossRefPubMed Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC, et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant. 2010;45(2):249–53.CrossRefPubMed
17.
Zurück zum Zitat Spasojevic I, da Costa LR, Horwitz ME, Long GD, Sullivan KM, Chute JP, et al. Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest. 2012;30(9):679–82.PubMedCentralCrossRefPubMed Spasojevic I, da Costa LR, Horwitz ME, Long GD, Sullivan KM, Chute JP, et al. Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest. 2012;30(9):679–82.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006;57(2):191–8.CrossRefPubMed Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006;57(2):191–8.CrossRefPubMed
19.
Zurück zum Zitat Dupuis LL, Sibbald C, Schechter T, Ansari M, Gassas A, Théorêt Y, et al. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Marrow Transplant. 2008;14(5):576–82.CrossRefPubMed Dupuis LL, Sibbald C, Schechter T, Ansari M, Gassas A, Théorêt Y, et al. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Marrow Transplant. 2008;14(5):576–82.CrossRefPubMed
20.
Zurück zum Zitat Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815–50.CrossRefPubMed Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815–50.CrossRefPubMed
Metadaten
Titel
Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration–time curve in pediatric hematopoietic stem cell transplant recipients
verfasst von
Erika Watanabe
Takuro Nishikawa
Kazuro Ikawa
Hiroki Yamaguchi
Takanari Abematsu
Shunsuke Nakagawa
Koichiro Kurauchi
Yuichi Kodama
Takayuki Tanabe
Yuichi Shinkoda
Kazuaki Matsumoto
Yasuhiro Okamoto
Yasuo Takeda
Yoshifumi Kawano
Publikationsdatum
01.11.2015
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1853-6

Weitere Artikel der Ausgabe 5/2015

International Journal of Hematology 5/2015 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.